The Committee adopted by consensus positive opinions for variations requiring assessment concerning quality-related changes for:

• Equioxx
• Onsior
• Simparica Trio, Felisecto Plus, MiPet Easecto, Simparica, Stronghold Plus (worksharing procedure)
• Vectormune ND, Newflend ND H9 (worksharing procedure)

The Committee adopted by consensus positive opinions for variations requiring assessment to align the product information with version 9.0 of the QRD template for:

• Credelio Plus
• Eravac
• Eryseng
• Eryseng Parvo
• Evalon
• Evant
• Hiprabovis IBR Marker Live
• Meloxoral
• Mhyosphere PCV ID
• Nasym
• Nobivac Myxo-RHD Plus
• Nobivac LeuFel, Leucogen (worksharing procedure)
• Rhiniseng
• Startvac
• Suvaxyn Circo+MH RTU
• Suvaxyn Circo
• Ubac
• Vepured

Maximum residue limits

The Committee agreed to include Varroa destructor calmodulin gene-specific double-stranded interfering RNA EP15 (naked unmodified dsRNA) as a new entry in the list of chemical-unlike biological substances not requiring a full MRL evaluation in accordance with Commission…